美国陪审团裁定安进捆绑销售药品违法,再生元获逾4亿美元赔偿金

智通财经网
May 16, 2025

美国特拉华州一个联邦陪审团裁定,安进$(AMGN)$违反美国反垄断法,强迫药品福利管理机构 $(PBM)$ 选择其胆固醇药物Repatha,而不是竞争药物Praluent,再生元制药公司$(REGN)$应获得4亿多美元的赔偿金。

特拉华州地方法院的陪审团于周四做出了支持再生元制药公司的判决,指控安进非法捆绑其抗炎药Enbrel和Otezla,以说服PBM选择Repatha而不是Praluent。

虽然Enbrel和Otezla不是心脏药物,但据称安进威胁拒绝向PBM支付回扣,除非它们选择Repatha而不是Praluent。再生元制药公司在新闻稿中表示:“安进阻止再生元在公平竞争的环境中竞争,并且不公平地阻碍患者获得Praluent。”

再生元赢得了1.356亿美元的补偿性赔偿和2.712亿美元的惩罚性赔偿。

Praluent是一种PCSK9抑制剂,由再生元和赛诺菲$(SNY)$根据全球合作协议开发,2024年全球销售额为7.65亿美元,其中美国销售额为2.417亿美元,同比增长约20%。

Repatha采用类似的机制来降低低密度脂蛋白$(LDL)$胆固醇,同年为安进带来22亿美元的销售额,同比增长约36%。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10